A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

Donald C. Goff*, Lawrence Herz, Thomas Posever, Vivian Shih, Guochuan Tsai, David C. Henderson, Oliver Freudenreich, A. Eden Evins, Iftah Yovel, Hui Zhang, David Schoenfeld

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

107 Scopus citations


Rationale: D-Cycloserine, a partial agonist at the glycine site of the N-methyl-d-aspartate receptor, has demonstrated inconsistent efficacy for negative and cognitive symptoms of schizophrenia. The strongest evidence for efficacy has come from studies using d-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less. Objective: To assess the efficacy for negative symptoms and cognitive impairment of d-cycloserine augmentation of conventional antipsychotics in a 6-month trial. Methods: Fifty-five schizophrenia patients with prominent negative symptoms, treated with conventional antipsychotics, were randomly assigned to treatment with D-cycloserine 50 mg/day or placebo for 6 months in a double-blind, parallel group design. Results: Twenty-six subjects completed the 6-month trial; drop-out rates did not differ between treatment groups. D-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery. Serum D-cycloserine concentrations did not correlate with response of negative symptoms. Conclusion: D-Cycloserine did not exhibit therapeutic effects in this trial, possibly reflecting the high drop-out rate, a narrow range of therapeutic serum concentrations, a modest magnitude of therapeutic effect for the selected outcome measures, or loss of efficacy over time. Because D-cycloserine is a partial agonist with relatively low affinity for the glycine site, the magnitude of potential therapeutic effect may be smaller than that achieved by the higher-affinity full agonists, glycine and d-serine.

Original languageAmerican English
Pages (from-to)144-150
Number of pages7
Issue number1
StatePublished - Apr 2005
Externally publishedYes

Bibliographical note

Funding Information:
Acknowledgements This study was supported by PHS RO1 MH54245, K24 MH02025, and P50 MH60450.


Dive into the research topics of 'A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients'. Together they form a unique fingerprint.

Cite this